Gabapentin Treatment of Cannabis Dependence
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cannabis Dependence
Intervention: gabapentin (Drug); Standardized behavioral therapy (Behavioral)
Phase: Phase 1/Phase 2
Status: Recruiting
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
Barbara J. Mason, Ph.D., Principal Investigator, Affiliation: The Scripps Research Institute- Pearson Center for Alcoholism and Addiction Research
Overall contact:
Kimberly R. Buffkins, Psy.D., Phone: 858-784-7465, Email: kbuffkin@scripps.edu
Summary
This is a study to evaluate the efficacy of the medication gabapentin in treating persons
with cannabis dependence.
Clinical Details
Official title: Gabapentin for Cannabis Withdrawal and Use
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Cannabis useCannabis withdrawal
Secondary outcome: SleepMood Craving Cannabis use consequences
Detailed description:
This is a 12-week, double blind, placebo controlled, dose ranging study to evaluate the
efficacy of gabapentin in treating outpatients with cannabis dependence. Counseling and
research assessments occur weekly throughout the 12-week treatment phase.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Males or females age 18-65 with cannabis dependence
- Meets DSM-IV-TR criteria for Cannabis Dependence
- Smoked marijuana at least once a week in the 90 days prior to study participation
- Willing to attend 12 weekly study visits and 1 follow-up visit
Exclusion Criteria:
- Currently meets DSM-IV-TR criteria for dependence on illicit substances other than
cannabis
- Significant medical disorders that will increase potential risk or interfere with
study participation
- Women with childbearing potential who are pregnant, nursing, or refuse to use a
reliable method of birth control
- Treatment with an investigational drug in the last month
Locations and Contacts
Kimberly R. Buffkins, Psy.D., Phone: 858-784-7465, Email: kbuffkin@scripps.edu
The Scripps Research Institute, La Jolla, California 92037, United States; Recruiting
Susan Quello, Phone: 858-784-7327, Email: squello@scripps.edu
Kimberly R. Buffkins, Psy.D., Phone: 858-784-7465, Email: kbuffkin@scripps.edu
Barbara J. Mason, Ph.D., Principal Investigator
Additional Information
Starting date: August 2006
Last updated: November 1, 2006
|
